CNSX:ATT - Abattis Bioceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseC$0.08Today's RangeC$0.08 - C$0.0852-Week RangeC$0.05 - C$0.74VolumeN/AAverage Volume1.42 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments. Receive ATT News and Ratings via Email Sign-up to receive the latest news and ratings for ATT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange CNSX Industry N/A Sub-IndustryN/A SectorN/A Current SymbolCNSX:ATT Previous Symbol CUSIPN/A CIKN/A Webwww.abattis.com Phone+1-604-3360881Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Abattis Bioceuticals (CNSX:ATT) Frequently Asked Questions What is Abattis Bioceuticals' stock symbol? Abattis Bioceuticals trades on the CNSX under the ticker symbol "ATT." What price target have analysts set for ATT? 1 Wall Street analysts have issued 12 month price objectives for Abattis Bioceuticals' stock. Their forecasts range from C$0.30 to C$0.30. On average, they expect Abattis Bioceuticals' share price to reach C$0.30 in the next twelve months. View Analyst Price Targets for Abattis Bioceuticals. What is the consensus analysts' recommendation for Abattis Bioceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abattis Bioceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abattis Bioceuticals. Has Abattis Bioceuticals been receiving favorable news coverage? Media coverage about ATT stock has trended positive this week, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Abattis Bioceuticals earned a coverage optimism score of 2.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near future. What other stocks do shareholders of Abattis Bioceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Abattis Bioceuticals investors own include Aphria (APHA), Surna (SRNA), CannTrust (CTST), Canopy Growth (WEED), Laird (LRD), Aurora Cannabis (ACBFF), Aurora Cannabis (ACB), MedReleaf (LEAF), Hays (HAS) and Opko Health (OPK). Who are Abattis Bioceuticals' key executives? Abattis Bioceuticals' management team includes the folowing people: Robert Abenante CPA, President, Chief Executive Officer, Director (Age 33)David Whitney, Chief Financial OfficerRene David, Chief Operating Officer, DirectorChristopher P. Cherry, Corporate Controller (Age 40)Hugh Oswald, IR Contact OfficerChristina Boddy, Corporate SecretaryPeter Gordon, DirectorJames Irving, DirectorShuang Xie, DirectorGuy P. Dancosse QC, Independent Director What is Abattis Bioceuticals' official website? The official website for Abattis Bioceuticals is http://www.abattis.com/. How can I contact Abattis Bioceuticals? Abattis Bioceuticals' mailing address is 224-970 Burrard St, VANCOUVER, BC V6Z 2R4, Canada. The company can be reached via phone at +1-604-3360881. MarketBeat Community Rating for Abattis Bioceuticals (CNSX ATT)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 70 (Vote Outperform)Underperform Votes: 76 (Vote Underperform)Total Votes: 146MarketBeat's community ratings are surveys of what our community members think about Abattis Bioceuticals and other stocks. Vote "Outperform" if you believe ATT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Dividend Achievers Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.